Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sartorius Completes Acquisition of Novasep's Chromatography Biz | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sartorius Completes Acquisition of Novasep’s Chromatography Biz

For the Bioprocess Solutions Division, the company now forecasts sales revenue growth of about 17 to 21 percent for 2022.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sartorius Stedim Biotech completed the acquirsition of Novasep‘s chromatography process equipment division. Novasep’s division expects to generated sales of approximately €40 million in 2020 with double-digit profit margins. The company employs approximately 100 people, with the majority working at its Pompey site in northern France, as well as the U.S., China and India. Financial details were not disclosed.

Novasep’s chromatography unit comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. Since 2018, the companies have been collaborating in the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively and that is expected to launch soon.

The acquisition is expected to generate additional non-organic sales revenue growth of around 1 percentage point in 2022. Sartorius has updated its sales revenue forecast for the current year: Consolidated sales revenue is now expected to increase by about 15 percent to 19 percent (previously about 14 percent to 18 percent), with non-organic growth from acquisitions projected to contribute about 2 percentage points (previously about 1 percentage point). 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters